Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
Department of Oncology-Pathology, Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.
Karlstads universitet, Fakulteten för ekonomi, kommunikation och IT, Avdelningen för nationalekonomi och statistik.ORCID-id: 0000-0002-9356-8767
Department of Surgery, Uppsala University, Uppsala, Sweden.
Vise andre og tillknytning
2014 (engelsk)Inngår i: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 50, nr 3, s. 517-524Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND:Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. In addition, impact on survival has been demonstrated. The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event.

MATERIALS AND METHODS:The cohort includes 1504 patients, diagnosed with a primary DCIS between 1986 and 2004. Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. ER and PR were identified by immunohistochemistry (IHC) and HER2 by silver-enhanced in situ hybridisation (SISH) as well as IHC.

RESULTS:ER (n=112), PR (n=113) and HER2 (n=114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively. The receptor conversion was both from negative to positive and from positive to negative with no general pattern being seen in spite of sub-dividing into in situ relapse and invasive relapse. However, primary DCIS was HER2 positive in 40.3% whereas in situ and invasive relapses were HER2 positive in 42.9% and 34.5% respectively.

CONCLUSIONS:Receptor conversion for ER, PR and HER2 status occurred between primary DCIS and corresponding local relapse in 10-30%. This study could not confirm that HER2 overexpression in primary DCIS had any impact on tumour progression to invasive cancer which has been proposed.

sted, utgiver, år, opplag, sider
Elsevier, 2014. Vol. 50, nr 3, s. 517-524
Emneord [en]
Breast cancer; DCIS; Ductal carcinoma in situ; ER; HER2; Hormonal receptor; Human epidermal growth factor receptor 2; Oestrogen receptor; PR; Progesterone receptor
HSV kategori
Forskningsprogram
Statistik; Nationalekonomi
Identifikatorer
URN: urn:nbn:se:kau:diva-33747DOI: 10.1016/j.ejca.2013.10.020ISI: 000330184400006PubMedID: 24275214OAI: oai:DiVA.org:kau-33747DiVA, id: diva2:748547
Tilgjengelig fra: 2014-09-19 Laget: 2014-09-18 Sist oppdatert: 2020-05-11bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Appelgren, Jari

Søk i DiVA

Av forfatter/redaktør
Appelgren, Jari
Av organisasjonen
I samme tidsskrift
European Journal of Cancer

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 86 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf